US jobs market blows past expectations, adding 256,000 jobs in December

Frankfurt - Delayed Quote EUR

CStone Pharmaceuticals (PH4.F)

0.2640

-0.0040

(-1.49%)

As of 3:29:01 PM GMT+1. Market Open.

CStone Announces Submission of Clinical Trial Application in Australia for CS2009, an Innovative PD-1/VEGF/CTLA-4 Trispecific Antibody

CStone Pharmaceuticals ("CStone", HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies, announced today the submission of clinical trial application in Australia for CS2009 (PD-1/VEGF/CTLA-4 trispecific antibody), a leading asset from the Company's Pipeline 2.0 to address various solid tumors. This first-in-human study has also been registered and published on Clinicaltrials.gov (NCT number: NCT06741644).

PR Newswire 18 days ago

CSPHF
0.00%
Infinity Logistics and Transport Ventures Among 3 Promising Penny Stocks

As global markets navigate a landscape marked by interest rate cuts from the ECB and SNB, and anticipation of further Fed action, investors are witnessing mixed performances across major indices. In this context, penny stocks—often associated with smaller or newer companies—continue to capture attention due to their unique blend of affordability and potential for growth. While the term may seem outdated, these stocks remain relevant as they can offer compelling opportunities when backed by...

Simply Wall St. 25 days ago

CSPHF
0.00%
1483.HK

1442.HK
Encouraging Efficacy and Safety: CStone Presents Latest Clinical Data on CS5001 for Advanced Lymphoma at the 66th ASH Annual Meeting

CStone Pharmaceuticals ("CStone", HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies, announced today the presentation of the latest clinical data for CS5001, an anti-ROR1 ADC and one of the leading assets in CStone Pipeline 2.0, at the 66th American Society of Hematology (ASH) Annual Meeting. These data highlight the compound's potential as a treatment for lymphoma.

PR Newswire last month

CSPHF
0.00%
CStone Announces MHRA Approval of Sugemalimab for First-Line Treatment of Non-Small Cell Lung Cancer (NSCLC) in the UK

CStone Pharmaceuticals (HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies, today announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved sugemalimab in combination with platinum-based chemotherapy as a first-line treatment for adult patients with metastatic non-small cell lung cancer (NSCLC) without EGFR-sensitive mutations or ALK, ROS1, RET genomic alterations. This marks the second

PR Newswire 2 months ago

CSPHF
0.00%
High Growth Tech Stocks In Hong Kong To Watch This September 2024

With global markets reacting positively to China's robust stimulus measures, Hong Kong's Hang Seng Index has seen a significant uptick, reflecting renewed investor confidence. In this favorable economic climate, identifying high-growth tech stocks becomes crucial for investors looking to capitalize on market momentum and technological advancements.

Simply Wall St. 3 months ago

CSPHF
0.00%
KSHTY

KUASF
High Growth Tech Stocks In Hong Kong Featuring SUNeVision Holdings And Two Others

The Hong Kong market has recently experienced mixed performance, with the Hang Seng Index gaining 2.14% amid broader global economic uncertainties and fluctuating investor sentiment. As inflation data and economic indicators continue to influence market dynamics, high-growth tech stocks in Hong Kong present intriguing opportunities for investors seeking to navigate these volatile conditions. In this article, we will explore three promising tech stocks in Hong Kong, starting with SUNeVision...

Simply Wall St. 4 months ago

CSPHF
0.00%
NDWTY

1686.HK
CStone Reports 2024 Interim Results and Recent Corporate Updates

CStone Pharmaceuticals (HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies, today reported interim financial results for 2024 and recent business highlights.

PR Newswire 4 months ago

CSPHF
0.00%
CStone Announces European Commission Approval of Sugemalimab (Cejemly®) as First-Line Treatment for Non-Small Cell Lung Cancer

CStone Pharmaceuticals ("CStone", HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies, today announced that the European Commission (EC) has approved sugemalimab (Brand name: Cejemly®) in combination with platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small-cell lung cancer (NSCLC) with no sensitizing EGFR mutations, or ALK, ROS1 or RET genomic tumour aberrations. Sugemal

PR Newswire 5 months ago

CSPHF
0.00%
CStone Announces European Medicine Agency CHMP Recommends Approval of Cejemly® (sugemalimab, anti-PD-L1) as First-Line Treatment for NSCLC

CStone Pharmaceuticals (HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending approval of sugemalimab in combination with chemotherapy as a first-line treatment for metastatic non-small cell lung cancer (NSCLC), which is one of the largest cancer indications and a le

PR Newswire 7 months ago

CSPHF
0.00%
CStone Announces Abstract Release of CS5001 (ROR1 ADC) First-in-Human Clinical Data on ASCO Website

CStone Pharmaceuticals ("CStone", HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies, today announced that the abstract containing the preliminary data from the first-in-human, global, multi-regional, phase 1a/1b study of CS5001 (ROR1 ADC) in patients with advanced solid tumors and lymphomas has been published on the website of the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting. Additional up-to-date clin

PR Newswire 7 months ago

CSPHF
0.00%
CStone Pharmaceuticals Reports 2023 Annual Results and Business Updates

CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, today reported 2023 annual results and recent business updates.

PR Newswire 9 months ago

CSPHF
0.00%
CStone Announces the Fifth Indication Approved for Sugemalimab in China as First-Line Treatment for Gastric Cancer

CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on the research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, today announced that the National Medical Products Administration (NMPA) of China has approved the supplemental biologics license application (sBLA) for sugemalimab (Cejemly®) in combination with fluoropyrimidine- and platinum-containing chemotherapy as a first-line treatment for unresectabl

PR Newswire 9 months ago

CSPHF
0.00%

Performance Overview

Return	PH4.F	HANG SENG INDEX
YTD	-2.22%	-4.88%
1-Year	+7.84%	+17.75%
3-Year	-66.37%	-18.85%